1436611-81-2

Upstream product

• 7250-67-1 1-(2-chloroethyl)pyrrolidine hydrochloride 
• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 
• 1436613-47-6 4-phenyl-1-(p-tolylsulfonyl)-3-[4-(2-pyrrolidin-1-ylethoxymethyl)-1-piperidyl]thieno[2,3-c]pyrazole 
• 1436613-26-1 N-[(Z)-[(2,5-dibromo-4-phenyl-3-thienyl)-[4-(2-pyrrolidin-1-ylethoxymethyl)-1-piperidyl]methylene]amino]-4-methyl-benzenesulfonamide 
• 1436613-17-0 (3Z)-2,5-dibromo-4-phenyl-N-(p-tolylsulfonyl)thiophene-3-carbohydrazonoyl chloride 
• 1436613-08-9 2,5-dibromo-4-phenyl-N'-(p-tolylsulfonyl)thiophene-3-carbohydrazide 
• 1436613-02-3 2,5-dibromo-4-phenyl-thiophene-3-carbonyl chloride 
• 1436612-96-2 2,5-dibromo-4-phenyl-thiophene-3-carboxylic acid 
• 1436612-90-6 ethyl 2,5-dibromo-4-phenyl-thiophene-3-carboxylate 
• 4815-36-5 ethyl 2-amino-4-phenyl-thiophene-3-carboxylate 
• 1248509-76-3 4-(2-pyrrolidin-1-ylethoxymethyl)piperidine 
• 1437774-69-0 tert-butyl 4-(2-pyrrolidin-1-ylethoxymethyl)piperidine-1-carboxylate 

Downstream Products

• 1436612-18-8 1-[4-phenyl-3-[4-(2-pyrrolidin-1-ylethoxymethyl)-1-piperidyl]thieno[2,3-c]pyrazol-1-yl]ethanone 

Relevant academic research and scientific papers

THIENO (2,3 - C) PYRAZOLES FOR USE AS POTASSIUM CHANNEL INHIBITORS

The present invention provides compounds of formula (I): wherein A, R1, R2, R3 IX, and Z are defined herein, which are potassium channel inhibitors. The invention further provides pharmaceutical compositions comprising the compounds of formula (I) and their use in therapy, in particular in treatment of diseases or conditions that are mediated by Kir3.1 and/or Kir3.4 or any heteromultimers thereof, or that require inhibition of Kir3.1 and/or Kir3.4 or any heteromultimers thereof.

THIENO [2, 3 - C] PYRAZOLES FOR USE AS POTASSIUM CHANNEL INHIBITORS

The present invention provides compounds of formula (I): wherein A, R1, R2, R3IX, and Z are defined herein, which are potassium channel inhibitors. The invention further provides pharmaceutical compositions comprising the compounds of formula (I) and their use in therapy, in particular in treatment of diseases or conditions that are mediated by Kir3.1 and/or Kir3.4 or any heteromultimers thereof, or that require inhibition of Kir3.1 and/or Kir3.4 or any heteromultimers thereof.